Coming Off a Compounded GLP-1: A Step-by-Step Transition Plan

Key takeaways

• First, confirm exactly what you are taking: the vial concentration and your dose in milligrams.
• Do not stop while you sort out supply. Stopping and waiting causes the most harm.
• Recheck the labs that show what treatment did for you before you change anything.
• You have more options than paying full price or quitting. Compare them side by side.
• A transition is easier to plan with a clinician than to improvise alone.

The short version. This page is for people whose compounded (custom-mixed by a pharmacy, not made in a factory) GLP-1 medication is about to run out. GLP-1 medications are semaglutide and tirzepatide: drugs that mimic a gut hormone to curb appetite and steady blood sugar. Do not stop suddenly. Do not assume your compounded dose maps one-to-one onto a brand pen. And do not treat this as a supply problem when it is really a planning chance. The six steps below are the order we work through with patients, and the order matters.

The regulatory background is in the FDA compounded GLP-1 ban and what it means for Michigan patients. This page is the plan.

Where Things Actually Stand, Briefly

Here is the short factual position, because the plan only makes sense against it. FDA found the tirzepatide injection shortage resolved on December 19, 2024. It found the semaglutide injection shortage resolved on February 21, 2025. FDA's enforcement discretion (its choice not to act against compounders during the shortage) then ended on a published schedule (FDA).

• February 18, 2025 for 503A tirzepatide.
• March 19, 2025 for 503B tirzepatide.
• April 22, 2025 for 503A semaglutide.
• May 22, 2025 for 503B semaglutide.

Separately, on April 30, 2026 FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List (FDA press announcement). The proposal published in the Federal Register on May 1, 2026. The comment period was extended to July 30, 2026 (Federal Register, June 26, 2026). It is a proposal, not a completed rule. As of 17 August 2026 we could not confirm a final FDA determination. This area moves. Check the FDA pages linked above rather than relying on this paragraph in six months.

Step 1: Establish What You Are Actually Taking

This comes first because it is the step most often skipped. Skipping it makes every later step guesswork.

Brand pens are set in milligrams: you dial a dose. Compounded semaglutide has usually come as a multi-dose vial at a concentration the pharmacy chose. You draw it with an insulin syringe marked in units. So many patients know their dose in "units" and have never been told the milligram figure. The milligram figure is the only number that transfers.

Write down three things before your appointment.

• The concentration in mg/mL printed on the vial.
• The volume you draw in millilitres.
• The resulting dose in milligrams.

Bring the vial and its label if you still have it.

This is not paperwork for its own sake. FDA's alert of July 26, 2024 documented patients told to draw a 5-unit (0.05 mL) dose who drew 50 units instead. That is a tenfold error. Prescriptions were also written for 25 units instead of 5, and 20 instead of 2. Some patients gave themselves five to 20 times the intended dose. They needed medical attention or a hospital stay (FDA). A meaningful number of people are not on the dose they believe they are on, in both directions.

Step 2: Do Not Stop While You Sort This Out

The most damaging response to a supply gap is to stop and wait to see what happens.

The STEP 1 trial extension shows why. It followed people for a year after once-weekly semaglutide 2.4 mg and the lifestyle program were withdrawn. Mean weight loss on treatment had been 17.3 percent. One year after stopping, they had regained 11.6 percentage points of that loss. That left them a net 5.6 percent below their starting weight. Cardiometabolic (heart and metabolic) improvements largely went back toward baseline (where they started) as well. The authors concluded that ongoing treatment is needed to keep the gains (Wilding et al., Diabetes Obes Metab 2022, PMID 35441470, DOI).

Two things follow. First, obesity behaves as a chronic condition. The response to stopping is a physical one, not a failure of willpower. Second, stopping is sometimes the right call, usually for cost. If so, it should be a planned taper with structure built in advance. It should not be an unplanned stop when the last vial runs out. That is step six.

Step 3: Recheck the Labs That Show What Treatment Achieved

A transition is the natural moment to find out what the medication has done for you. The scale only partly answers that.

We generally look at seven things.

• HbA1c (your average blood sugar over the past three months).
• Fasting insulin and glucose.
• A full lipid panel (a cholesterol and blood-fat test).
• Liver enzymes.
• Thyroid function.
• Inflammatory markers.
• Body composition (how much of your weight is muscle versus fat) where available.

Body composition matters more than people expect. Keeping lean mass through a transition is a large part of whether your result holds.

This data does double duty. It guides the clinical decision. It is also the paperwork that supports an insurance prior authorization (your insurer's advance approval) or appeal if you need one.

Want to know what this would mean for you?
A 30–45 minute visit in Ann Arbor to confirm your true dose and map your options, with the $35 applied toward your treatment plan.
Book your $35 first visit Call (734) 436-3357

Step 4: Map Your Real Options, With Real Numbers

There are more paths than "pay full price or quit". Lay them out side by side before you decide:

• Switch to the approved product for the same molecule. Pursue insurance coverage where a qualifying indication (a diagnosis the drug is approved to treat) exists.
• Switch molecules where it makes clinical sense. Coverage and access sometimes differ between semaglutide and tirzepatide products, even when the clinical case is similar.
• Manufacturer self-pay channels. These have changed a great deal since 2025, so check them directly rather than assuming. Current figures and sourcing are covered in compounded vs brand semaglutide. Verify pricing with the manufacturer before budgeting, since these programs change often.
• A planned, structured step down if continuing is not affordable.

What we will not do is engineer a workaround for a regulatory position. If a route is not available, we will say so plainly. We will not point you somewhere unregulated. Some products are sold without a prescription, labelled "for research use only", or require you to mix powder yourself. Those sit outside the legitimate supply chain, and FDA has warned about exactly that pattern.

Step 5: Titrate Deliberately — Do Not Assume Dose Equivalence

Many people assume a compounded milligram dose maps exactly onto the same brand milligram dose. That assumption is what produces avoidable nausea in week one.

In practice, we first confirm the true milligram dose from step one. We then usually restart one step below it and retitrate (adjust the dose back up step by step) over about four to six weeks. We judge each step by appetite control and how well you tolerate it. That is a small delay in exchange for a far smoother month. It also cuts the chance that someone quits a treatment that was working because the first two weeks were miserable.

Expect closer contact during this window: roughly every two weeks while the dose is moving, then spacing out once you are stable.

Step 6: Build the Maintenance Floor Before You Need It

You may be continuing on an approved product or stepping down. Either way, the habits that protect your result should be in place before the transition, not improvised after regain has started.

In practice, that means four habits.

• A protein target you actually hit daily.
• Resistance training at least twice a week to defend lean mass.
• Sleep treated as part of the protocol, not an afterthought.
• A monitoring interval booked in the calendar rather than left to whenever something feels wrong.

What I see in clinic: the people who transition smoothly almost always started this step a month early. The ones who struggle usually waited to see whether they would need it.

What This Looks Like as a Consultation

The first visit covers four things.

• Your current regimen in real numbers.
• Your dosing history and side effects.
• Your weight and lab trends.
• Your insurance position.

Labs are usually ordered before or during that visit, with results back within about a week.

Most people leave with a written transition plan. It lists medication options with their costs, a dosing schedule, and monitoring intervals. Follow-up runs about every two weeks through the transition. It then settles into a longer cycle with periodic metabolic labs once you are stable.

The consultation is $35, applied toward your treatment plan if you proceed.

Frequently Asked Questions

My supply ends this month. What do I do first?

Confirm your true dose in milligrams, and book a review before your last dose rather than after it. Those two things, in that order, prevent most of the avoidable problems.

Can I just stop and restart later when I can afford it?

You can, but know what the data show. In the STEP 1 extension, people regained roughly two-thirds of their lost weight in the year after stopping. Cardiometabolic markers largely went back toward baseline (PMID 35441470, DOI). If cost means stopping, plan the stop rather than letting it happen to you.

Is my compounded dose the same as the brand dose?

Not reliably, and you should not assume it. Work out the milligram dose from the vial concentration and the volume you draw. Then retitrate step by step rather than carrying the number across.

Can I still get a compounded version?

The broad, shortage-based permission ended in 2025 on the schedule above. Compounding for a documented individual clinical need that the approved product cannot meet is a narrow and separate question. It is a clinical determination, not a preference. Cost alone does not create that need.

Will I get side effects again when I switch?

Most people do not. A minority get mild, short-lived nausea in the first week or two. Raising the dose more slowly usually resolves it. That is exactly why step five is deliberate rather than fast.

What if my insurance denies coverage?

Denials can often be appealed with proper clinical documentation. That is one reason step three comes before step four. We prepare that documentation and handle prior authorizations and appeals where coverage is plausible.

Could compounding become permitted again?

It could, if a genuine shortage were declared again. That is how the mechanism works. The April 2026 proposal would close the separate 503B bulks pathway for good if finalised. We could not confirm a final determination as of 17 August 2026.

Talking It Through in Ann Arbor

Gandhi Bhattarai, FNP-BC, PMHNP-BC, Anti-Aging/Functional Medicine BC, is a triple board certified nurse practitioner. We are at 2217 Packard St #15, Ann Arbor, MI 48104. We are open Thursday through Monday, 10am to 7pm, and closed Tuesday and Wednesday. Parking is free and directly outside, with no meters and no parking structure. Suite 15 is down a flight of stairs. If stairs are difficult for you, please call (734) 436-3357 before your visit so we can make arrangements.

Call (734) 436-3357 or book your $35 first visit. The consultation is $35, applied toward your treatment plan. Cash pay, HSA and FSA accepted.

References

1. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PMID 35441470. doi:10.1111/dom.14725
2. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.
3. U.S. Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B Bulks List, April 30, 2026.
4. Federal Register. List of bulk drug substances for which there is a clinical need under section 503B; extension of comment period, June 26, 2026.
5. U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded semaglutide injectable products, July 26, 2024.

Clinical information on this page is drawn from articles retrieved from PubMed and from primary FDA sources, and is provided for education. It is not medical advice, not legal advice, not a diagnosis, and not a promise of any individual result. Regulatory status reflects sources verified on 17 August 2026 and may have changed since.